du Toit J I, Anderson S D, Jenkins C R, Woolcock A J, Rodwell L T
Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Allergy Asthma Proc. 1997 Jan-Feb;18(1):7-14. doi: 10.2500/108854197778612817.
Inhalation of histamine is commonly used to assess the severity of and to monitor treatment of asthma. Histamine causes airways to narrow by acting directly on specific receptors. Hyperosmolar saline causes airways of asthmatics to narrow indirectly by endogenously mediated events that are potentially modified by drugs used to treat asthma. We wished to determine if hyperosmolar saline (S) is a useful challenge for assessing the airway responsiveness of asthmatic subjects being treated with steroids and to compare changes in airway responses to those changes observed with histamine (H). The airway responses to S and H were assessed by the dose of aerosol provoking a 20% fall in FEV1 and the percent fall in FEV1 per unit dose of aerosol inhaled-the dose response slope (DRS). We studied asthmatic subjects before and during treatment with budesonide-1000 micrograms per day. There was a significant correlation (Spearman's) between PD20 to H and S and DRS to H and S after budesonide (P < 0.05). After 2 months of treatment; the mean PD20 (95% CI) was increased 4.6 (2.5, 8.6) fold to H, and 9.7 (4.2, 22) fold to S, (P = NS) the DRS reduced 7.0 (4.3, 11.5) fold to H and 16.6 (8.4, 33) fold to S (P = NS). Responsiveness to H, measured by PD20 remained throughout the treatment, whereas five subjects did not record a 20% fall after S and the DRS decreased to values close to those we measured in healthy subjects. In conclusion, challenge with 4.5% sodium chloride can be used to assess the early benefits of treatment with aerosol steroids.
吸入组胺常用于评估哮喘的严重程度并监测哮喘治疗。组胺通过直接作用于特定受体使气道变窄。高渗盐水通过内源性介导的事件间接使哮喘患者的气道变窄,这些事件可能会被用于治疗哮喘的药物所改变。我们希望确定高渗盐水(S)是否是评估接受类固醇治疗的哮喘患者气道反应性的有用激发剂,并将气道反应的变化与组胺(H)引起的变化进行比较。通过引起第一秒用力呼气容积(FEV1)下降20%的气雾剂剂量以及每吸入单位剂量气雾剂后FEV1的下降百分比——剂量反应斜率(DRS)来评估对S和H的气道反应。我们在哮喘患者接受布地奈德(每天1000微克)治疗前和治疗期间对其进行了研究。布地奈德治疗后,对H和S的激发剂量(PD20)以及对H和S的DRS之间存在显著的相关性(斯皮尔曼相关性)(P < 0.05)。治疗2个月后,对H的平均PD20(95%置信区间)增加了4.6(2.5,8.6)倍,对S增加了9.7(4.2,22)倍,(P = 无显著差异)对H的DRS降低了7.0(4.3,11.5)倍,对S降低了16.6(8.4,33)倍(P = 无显著差异)。通过PD20测量的对H的反应性在整个治疗过程中保持不变,而有5名受试者在接受S激发后未记录到FEV1下降20%,并且DRS下降至接近我们在健康受试者中测量的值。总之,用4.5%氯化钠进行激发可用于评估气雾剂类固醇治疗的早期疗效。